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HUMAN STEM CELL COMPOSITIONS AND METHODS

REFERENCE TO RELATED APPLICATION
This is a continuation-in-part of U.S. Pat, application Ser. No. 07/919,447 filed Jul. 27, 1992, now abandoned, which is hereby incorporated by reference in its entirety. This application was made with government support under the National Institutes of Health grants R01 CA45279 entitled, "Purification of Primitive Hematopoietic Progeni tor Cells' and R01 HLA-6548 entitled "In Vitro Reconstitu tion of Normal Human Hematopoiesis". The government has certain rights in this invention.
BACKGROUND
The present invention relates to pluripotenthematopoietic stems cells (PHSC's) and to methods for their isolation and S.
Evidence shows that PHSC's are responsible for the generation of all of the formed elements of blood, including for instance the myeloid, lymphoid, erythroid and mega karyocytic lineages. However, despite this understanding and continued extensive efforts in industry and academia, PHSC's have not been identified and isolated in a pure form.
The high level interest in purifying stem cells speaks to the utility that will be found with enriched stem cell com positions. For example, availability of pure or substantially pure stem cells will provide a means to identify factors which cause or prevent dedication to specific lineages. Pure or substantially pure stem cells may also be used in grafts or transplantations (including autotransplants, allogeneic trans plants and others), for example to provide immediate and/or long term health benefits due to the presence and mainte nance of the graft or transplant in the host, to provide chimeras, etc. For example, human stem cells may be isolated and used as stem cell grafts for in utero transplan tation into human fetuses diagnosed with a genetic disorder which can be corrected by normal BM transplantation. The known similar methods utilize human fetal liver cells as grafts which in most all cases would be from unrelated mismatched donors and in most instances not available at will. Autotransplants of pure stem dells could be potentially useful in several leukemias where purified stem cells could be devoid of cancer cells and might therefore provide a disease-free graft. Enriched stem cell compositions also represent excellent targets for gene transfer studies and in gene therapy in which cells are genetically manipulated, e.g. by transfection and transduction. In this manner, propagation of a gene intro duced or altered by the genetic manipulation in progeny cells can be assured by the cells' capacity for self-renewal. Stem cell compositions may also be used in treating and in research for treating neoplastic conditions such as leukemias, lymphomas, and others.
Researchers in the area have employed various approaches to enrich for stem cells, which are highly rare and currently believed to represent approximately 0.01 to 0.05%. of human bone marrow cells. Schemes to enrich for stem cells have often attempted to selectively isolate cells lacking markers known to exist on differentiated hemato poietic lineages, but having markers known to exist on stem cells. Thus, both negative and positive selection procedures have been employed. The presence of stem cells in the isolated cell fractions is then demonstrated by assessing their capacity to self-renew and differentiate to the various blood cell lineages. The use of labeled monoclonal antibodies and flow cyto metric cell sorting to isolate fractions enriched in stem cells has been successful to a limited degree. Due to the avail ability of a large number of monoclonal antibodies which can be used for this purpose, none of which directly have identified stem cells, many combinations of antibodies can be employed. Still, by these previous efforts, cells which possess one or more of the functional characteristics attrib uted to stem cells, but not all, have been obtained.
Various other methods for enriching, isolating and puri fying human stem cells have also been generally applied in the fields of experimental hematology and clinical medicine. Examples of such methodologies include counterflow cen trifugal elutriation, immunomagnetic separation, panning, and the use of the avidin-biotin interaction over different matrices. Although each of these methodologies has been successful to a limited degree, they have all failed to isolate cells that could be phenotypically characterized as more than just CD34" cells.
In light of this and other extensive background in the area, there remain needs for new PHSC-enriched compositions and methods for obtaining them. Needs also exist for meth ods for grafting hosts with PHSC-containing compositions whereby the grafted cells are maintained and differentiated in the host. The present invention addresses these and other needs.
SUMMARY OF THE INVENTION
One preferred embodiment of the invention provides a human-PHSC containing cellular composition comprising a substantially homogeneous population of human hemato poietic cells characterized as CD34, HLA-DR, and c-Kit receptor positive (KR) and capable of in vitro self-renewal and differentiation to members of at least the erythroid, myeloid, and megakaryocytic lineages.
Another preferred embodiment of the invention provides a method for recovering a human-PHSC enriched cell frac tion from its mixture with committed progenitors and dedi cated lineages thereof, the cell fraction being capable of in vitro self-renewal and differentiation to members of at least the erythroid, myeloid and megakaryocytic lineages. The method includes the step of separating from the cellular mixture a substantially homogeneous population of human hematopoietic cells characterized as CD34, HLA-DR, KR. This may be conveniently accomplished by treating the cellular mixture by counterflow centrifugal elutriation to obtain a first cell fraction enriched, e.g. 2-fold or more enriched, in CD34, HLA-DR cells as compared to the cellular mixture, combining the first fraction with fluorochrome-labeled antibodies to markers including CD34, HLA-DR, and KR, each of said fluorochromes dif fering from the other, and recovering the substantially homogeneous CD34", HLA-DR, KR'population by means of the fluorochromes, e.g. by cytometric cell sorting tech niques. In this regard, sorting as to a specific marker can be done in an individual operation, or sorting as to some or all of the markers can be simultaneously accomplished.
Another preferred embodiment of the invention provides a human-PHSC containing cellular composition comprising a substantially homogeneous population of human hemato poietic cells isolated from human peripheral blood, charac terized as CD34, HLA-DR and capable of in vitro self renewal and differentiation to members of the at least the erythroid, myeloid, and megakaryocytic lineages. Such cell populations have proven to initiate long term cell cultures in a fashion similar to that observed in cultures initiated using 5, 672, 346 3 their counterpart cells isolated from bone marrow. Preferred populations of this embodiment are characterized as sub stantially CD34, HLA-DR, KR.
Another preferred embodiment of the invention provides a method for obtaining a human-PHSC enriched cell popu lation capable of in vitro self-renewal and differentiation to members of at least the erythroid, myeloid and megakaryo cytic lineages. The method includes the step of separating from peripheral blood a substantially homogeneous popu lation of human hematopoietic cells characterized as CD34, HLA-DR. In a preferred mode this method includes the step of mobilizing PHSC's to the peripheral blood, for instance by the administration of suitable agents therefor.
Another preferred embodiment of the invention provides a human-PHSC containing cell population in a culture medium and having an expanded number of cells charac terized as CD34, HLA-DR. The population is preferably stimulated by a combination of cytokines effective to pro vide the expansion of the number of CD34, HLA-DR cells.
Another preferred embodiment of the invention relates to a method of obtaining persistent maintenance of grafted human hematopoietic cells in a mammal. The method includes the step of grafting the mammal in utero with a cellular composition enriched in human hematopoietic cells characterized as CD34, HLA-DR and capable of in vitro self-renewal and differentiation to members of the lymphoid, myeloid, erythroid and megakaryocytic lineages. By the method, successful treatments can be obtained, as can chimeras in large animal systems such as ruminant mammals, e.g. sheep, which have bone marrow containing human hematopoietic cells characterized as CD34. HLA DR, and further having peripheral human blood cells characterized as CD45, CD14, CD4, CD8, CD19 and CD16/CD56. These grafted mammals have also shown to be highly persistent in maintaining hematopoietic charac teristics of the graft, for example well beyond grafting and birth.
Additional embodiments, features and advantages of the present invention will be apparent from the following description. FIG. 5a shows absolute viable cell numbers in stromal cell-free cultures initiated with PB CD34 HLA-DR cells obtained from Group A and Group C patients. Each culture was initiated with 1x10" cells/ml. Each point represents the mean-SEM of 4 Group A patients, 2 Group B patients and 6 Group C patients.
F.G. Sib shows absolute number of CFU-GM in stromal cell-free cultures initiated with PB CD34 HLA-DR cells from Group C patients. Each point represents the mean-SEM of 4 Group A patients, 2 Group B patients and 6 Group C patients.
FIG . 6 shows the results of replating of primary HPP-CFC colonies as described in the Examples. Primary HPP-CFC colonies were plucked on day 28. Cells from individual primary colonies were replated in methylcellulose under the same conditions used in the primary colony assay. Second ary CFU-GM-derived (hatched bars) and HPP-CFC (solid bars) colonies were enumerated 14 and 28 days later, respec tively.
DESCRIPTION OF THE PREFERRED EMBODMENTS
For the purposes of promoting an understanding of the principles of the invention, reference will now be made to certain embodiments and specific language will be used to describe the same. It will nevertheless be understood that no limitation of the scope of the invention is thereby intended, such alterations, further modifications and applications of the principles of the invention as described herein being contemplated as would normally occur to one skilled in the art to which the invention relates.
Human-PHSC containing cellular compositions are pro vided which include substantially homogenous populations of human hematopoietic cells characterized as CD34, HLA-DR, KR. The CD34, HLA-DR, KR cells are capable of in vitro self-renewal and differentiation to mem bers of at least the erythroid, myeloid and megakaryocytic lineages. The CD34, HLA-DR, KR cells are also capable of massive expansion of cell numbers. In addition to the above, preferred populations of the invention are further characterized as CD15, CD71 and/or rhodamine 123 dull.
The substantially CD34" HLA-DR, KR populations may be isolated from their cellular mixtures with committed progenitors and differentiated lineages. For example, the cellular mixture can be adulthuman bone marrow, umbilical cord blood, fetal liver or peripheral blood.
In an early stage, the cellular mixture is treated so as to substantially remove cells carrying markers associated with 5,672,346 5 dedicated lineages. Preferably, this treatment will resultinat least a 2-fold enrichment of cells lacking the mature markers associated with dedicated lineages, more preferably at least 5-fold and most preferably about 10-fold or more. For example, it is preferred to obtain a fraction enriched for CD34, HLA-DR cells in these amounts. This may be accomplished in any suitable manner, for instance by coun terflow centrifugal elutriation, soybean agglutination, enrichment with magnetic beads, affinity chromatography over activated matrices, etc. However, the applicants have found it to be highly preferred to accomplish this result by counterflow centrifugal elutriation, and less preferred to use magnetic separation since this latter method does not tend to enrich as highly for CD34, HLA-DR cells.
After the early separation to an enriched fraction as described above, a substantially homogeneous population of CD34, HLA-DR, KR cells is obtained therefrom. This may be conveniently accomplished by employing an anti body to extracellular portions of KR in conjunction with antibodies to CD34 and HLA-DR, coupled with fluorescence-activated cell sorting.
As an example, the CD34", HLA-DR population of human marrow cells contains the blast colony-forming cell (CFU-B1), the high proliferative potential colony-forming cell (HPP-CFC), and the cell responsible for initiating long-term hematopoiesis in vitro (LTBMC-IC). Further frac tionation of the CD34, HLA-DR population based on KR expression (greater than 33% of the CD34 DR cells expressed KR) and utilization of assays for these primitive cells indicated the presence of human PHSC's in the CD34, HLA-DR, KR fraction. In particular, the CD34 HLA DR', SR-1" cell population contained the majority of the more differentiated progenitor cells, including the granulocyte-macrophage-colony-forming-unit (CFU-GM); burst-erythroid-forming-unit (BFU-E); CFU-granulocyte, erythrocyte, macrophage, and megakaryocyte; and the CFU megakaryocyte. By contrast, the CD34, HLA-DR, SR-1 cell population contained fewer of these more differentiated progenitor cells but exclusively contained the more primi tive progenitor cells, the BFU-megakaryocyte, HPP-CFC and LTBMC-IC. The overall progenitor cloning efficiency of the CD34, HLA-DR, SR-1 subpopulation was greater than 7%. Both the CD34, HLA-DR and CD34, HLA DR" cell subpopulations lacking KR expression contained few assayable hematopoietic progenitor cells.
Long term bone marrow cultures initiated with CD34, HLA-DR, SR-1" cells generated assayable progenitor cells of at least 2 lineages for 10 weeks, in contrast to CD34, HLA-DR, SR-1 cells which failed to initiate such suc cessful cultures. In these long-term cultures, CD34, HLA DR, SR-1" cells were capable of massive expansion of cell numbers to over 250-fold as compared to a 10-fold increase by SR-1T cells. Thus, the applicants have demonstrated that human bone marrow cells which express CD34 and KR but not HLA-DR represent a primitive population of progenitor cells that includes the PHSC.
The invention also provides substantially homogeneous CD34, HLA-DR cell populations isolated from peripheral blood, which have proven to possess advantages in estab lishing long term cultures as compared to counterpart popu lations isolated from bone marrow. In particular, long-term hematopoietic cell suspension cultures initiated with CD34 HLA-DR cells isolated from peripheral blood produced greater numbers of total cells and progenitor cells than long-term suspension cultures initiated with CD34 HLA DR cells obtained from bone marrow. These cell popula tions can be obtained in accordance with the invention by mobilizing progenitor cells and PHSC's into the peripheral blood and then isolating the desired population from col lected peripheral blood by employing, for example, sorting techniques as described herein. The mobilization is advan tageously achieved by administering cyclophosphamide to the subject followed by the administration of one or more hematopoietic growth factors, for example interleukin-3 (IL-3)-granulocyte-colony stimulating factor (G-CSF), IL-3-granulocyte-macrophage-colony stimulating factor (GM-CSF) or a recombinant GM-CSF/IL-3 fusion protein.
The invention further provides human PHSC-containing cellular compositions in culture medium in which the num ber of CD34, HLA-DR cells is expanded. Long term cell cultures of the invention include stimulation by a combina tion of cytokines effective to provide the expansion of the CD34, HLA-DR cell number, and are preferably initiated by a human-PHSC containing cell population characterized as CD34, HLA-DR, CD15, rhodamine 123 dull (R). Useful cell populations for such initiations may also be further characterized as KR and/or CD71. Preferred cell cultures of the invention are maintained by the addition of an effective combination of cytokines includ ing c-kit ligand. For example, preferred cell cultures main tained by the periodic addition of c-kitligand in combination with the above-mentioned GM-CSF/IL-3 fusion protein, by day 21 after initiation, had a greater than twofold increase in the number of assayable HPP-CFC cells. Further, periodic analysis of cells harvested from these preferred long term cell cultures showed that the number of CD34, HLA-DR cells increased by more than fifty-fold by day 21. Individual HPP-CFC colonies were also serially cloned to examine the in vitro expansion of HPP-CFC. Secondary cloning of individual, day 28 primary HPP-CFC demonstrated that 46% of these colonies formed an average of nine secondary granulocyte-macrophage-colony-forming-unit (CFU-GM) derived colonies, whereas 43% of primary HPP-CFC gave rise to between one and six secondary HPP-CFC colonies and 6 to 26 CFU-GM.
As indicated above, other aspects of the invention provide methods for obtaining persistent maintenance of grafted hematopoietic cells in a mammal. These methods involve grafting a mammal in utero with a cellular composition enriched in human hematopoietic cells characterized as CD34, HLA-DR. In this regard, the cellular composition used for the graft may also be one according to the above described embodiments of the invention. The cellular com positions of the invention will also find use in gene transfer and gene therapy studies, reconstituting irradiated marrow populations, treating neoplastic conditions, to purge bone marrow of neoplastic cells as a means of preparing autolo gous bone marrow grafts, and other similar applications. The cellular compositions can be maintained in conventional long-term cultures, may be frozen and stored in liquid nitrogen pending later use, etc.
To promote a further understanding of the invention and its preferred embodiments, advantages and features, the following Examples are provided. It will be understood, however, that these Examples are illustrative and not limit ing in nature. N.J.) at 750 g. LDMC cells were suspended in phosphate buffered saline (PBS), pH 7.4, containing 5% fetal calf serum, 0.01% EDTA withvol., and 1.0 g/l D-glucose, and injected into a Beckman counterflow centrifugal elutriation (CCE) system at 10° C. at a rotor speed of 1,950 rpm using a JA-17 rotor and standard separation chamber (Beckman Instruments, Inc., Palo Alto Calif.). Effluent samples eluting at flow rates between 12 and 14 mL/min (FR 12-14; presort) were collected as previously described by Brandt et al., J. Clin. Invest, Vol. 82, p. 1017 (1988 . The FR 12-14 cell population contained greater than 70% of progenitor cells and was used in subsequent steps.
MoAbs
The following three purified mouse antihuman (m. O h) MoAbs were used as immunologic probes for cell sorting experiments: (1) m ot, h CD34.IgG (Becton Dickinson Immunocytometry Systems, Mountain View, Calif.); (2) m ot h HLA-DR conjugated with phycoerythrin (HLA DRPE). IgG (Becton Dickinson); (3) moth SR-i. IgG (see Broudy et al., Blood, Vol. 79, p. 338 (1992) ). In addition, m oh MoAbs to CD15, and CD71 were used as described by Brandt et al., J. Clin. Invest, Vol. 86, p. 932 (1990) . The supravital mitochondrial membrane specific dye rhodamine 123 (R') was used as previously described by Srour et al., Cytorietry, 12, 179 (1991 Brandt et al., J. Clin. Invest, Vol. 86, p. 932 (1990) ).
The cells from each population were classified by per forming differential cells counts on Wright-Giemsa-stained cytocentrifuge cell preparation using established morpho logic criteria. Each population of cells was also assayed for various classes of human hematopoietic progenitor cells using procedures described below.
Recombinant Human Hematopoietic Cytokines The following three purified recombinant human hemato poietic cytokines were used as colony-stimulating factors in these experiments: (1) LTBMC System LTBMCs lacking preestablished stromal cell layers were initiated and maintained as described in Brandt et al., J. Clin, Invest, Vol. 86, p. 932 (1990); Brandt et al., Blood, Vol. 79, p. 634 (1992); and Briddell et al., Blood, Vol 79, p. 332 (1992) . Briefly, 35-mm polystyrene tissue culture dishes containing 1 mL IMDM with 10% vol/vol fetal bovine serum (Hyclone, Logan, Utah) were inoculated with 10' of either the CD34 HLA-DRSR-1 or the CD34 HLA-DR SR-1 marrow subpopulation obtained after FACS and incu bated at 37° C. in 100% humidified 5% CO, in air. At inoculation, and every 48 hours thereafter, 1 mL cultures received both 1.0 ng IL-3 and 10.0 ng KL. To address the possibility that CD34" HLA-DRT SR-1 cells might be responsive to other cytokines, we established LTBMCs initiated with these cells to which either GM-CSF/KL or FP/KL were added at 48-hour intervals. These two combi nations proved to be inferior to the IL-3/KL combination in progenitor cell production and length of viable culture duration from LTBMCs. At weeks 2, 4, 6, 8, 10, and 12, the cultures were demidepopulated by removal of one-half the culture volume, which was replaced with fresh media. Cells in the harvested media were counted, divided, and assayed in both of the subsequently described progenitor cell assay systems.
5,672,346 9 Progenitor Cell Assay Systems Serum-containing methylcellulose assay system. Sorted cells or cells harvested after the demidepopulation of LTBMCs, were assayed for their ability to produce CFU-GM-, BFU-E-, CFU-GEMM-, and HPP-CFC-derived colonies in a serum-containing methylcellulose assay sys tem as described in Brandt et al., J. Clin, Invest, Vol. 82, p. 1017 (1988 and Brandt et al., J. Clin. Invest, Vol. 86, p. 932 (1990) One nanogram of IL-3, 10.0 ng KL, and 2500 ng Epo/mL culture were used as sources of colony-stimulating activity (CSA). Cultures initiated were incubated for 28 days at 37° C. in 100% humidified 5% CO in air. CFU-GM-, BFU-E-, and CFU-GEMM-derived colonies were scored after 14 days, while HPP-CFC-derived colonies were scored after 28 days of culture, according to previously established morphologic criteria (Brandt et al., J. Clin. Invest, Vol. 82, p. 1017 (1988 and Brandt et al., J. Clin. Invest, Vol. 86, p. 932 (1990) ) HPP-CFC-derived colonies are defined by both the colony size and time of appearance in culture as previ ously described (McNiece et al., Exp. Hematol, Vol. 19, p. 226 (1991); Brandt et al., Blood, Vol. 79, p. 634 (1992) Initially, the FR 12-14 cells obtained after CCE were analyzed for expression of CD34, HLA-DR, and KR. Data obtained from these three separate marrow specimens showed that 6.5%+1.4% of these FR 12-14 cells expressed CD34 (CD34"). HLA-DR cells comprised an average of 68.1%t 17.9% of the CD34 cell A morphologic analysis of the four CD34 marrow sub populations from two separate BM donors, fractionated on the basis of HLA-Dr and KR expression, is provided in Table 2 . Cell populations expressing the KR (CD34 HLA DR SR-1, CD34* HLA-DRSR-1') largely resembled blast cells. Cell populations not expressing the KR (CD34 HLA-DRSR-1, CD34 HLA-DR'SR-1) contained more differentiated myeloid elements. There were no observable MK elements present in any of the populations analyzed. All four cell populations were directly assayed for whereas CFU-MK generation persisted for 10 weeks. In hematopoietic progenitor cell enrichment (CFU-GM, BFU E. CFU-GEMM, CFU-MK, BFU-MK, HPP-CFC). In Table   3 , the progenitor cell enrichment of each population is shown. The majority of the most primitive progenitor cells, the FBU-MK and HPP-CFC, were detected in the CD34
HLA-DR SR-1' population. The majority of the more differentiated progenitor cells, the CFU-GM, BFU-E, CFU GEMM, and CFU-MK, were present in the CD34 HLA DR SR-1 cell population. CD34 HLA-DR" SR-1 cells had a cloning efficiency of 31.4% whereas the CD34' HLA-DR SR-1" cell population had an overall 7.3% clon ing efficiency. Although the CD34 HLA-DR'SR-1 cell population contained significant numbers of progenitor cells (16.9% cloning efficiency), the numbers were far less than its SR-1 counterpart. Three groups of patients with breast cancer (Groups A, B and C) were involved in this study.
Group A ( Values are the mean number of derived coloniest SD of data obtained from duplicate assays performed on two separate occasions.
Sorted cells were cultured at a concentration of 10 mL in a serum-containing methylcellulose assay system with 10ng L-3/mL, 100 ng KLim, and 2500 ng Epo/mL.
Sorted cells were cultured at a concentration of 10 mL in a serum-depleted fibrin clot assay system with 1.0ng IL-3/mL and 100 ng KL/mL.
The cellular production of each type of LTBMC (CD34" The ability of these LTBMCs to produce assayable pro genitor cells is shown in FIGS. 2, 3, and 4. The CD34 HLA-DR SR-1'-initiated LTBMCs produced greater than 6.0x10 CFU-GM during the period of culture, indicating a greater than 10-fold increase in the number of these pro genitor cells from the initial cellularinoculum (550.050.0) (FIG. 2) . In FIG. 3A and B, progenitor cell production of other lineages is shown for both LTBMCs. Far greater production of BFU-E. CFU-GEMM, and CFU-MK was observed in the LTBMC initiated with CD34 HLA-DR SR-1 cells (FIG. 3A and B) . BFU-E and CFU-GEMM production by these cultures was sustained for 4 weeks, Helsinki. The absence of metastatic disease in each of these 6 patients was determined by morphological analysis of marrow aspirates and biopsies. Cyclophosphamide (HD CTX) (7 g/m) was divided into 5 doses and administered intravenously for 1 hour every 3 hours. Beginning on day +1 after HD-CTX, patients were then intravenously given com binations of hematopoietic growth factor(s) (C-HGF) with the dual aim of accelerating marrow recovery and enhancing the circulation of hematopoietic progenitors after HD-CTX induced pancytopenia. The type of hematopoietic growth factor(s), doses, and schedules for each patient are shown in Group B included 6 breast cancer patients with identical clinical characteristics to those in Group A who did not enroll in the HD-CTX-C-HGF protocol described above. Informed consent from these patients was obtained accord ing to similar guidelines outlined above.
Group C included 8 breast cancer patients who were treated but not enrolled in the HD-CTX-C-HGF protocol described above. These 8 women had locally advanced (Stage IIIB) or metastatic (Stage IV) breast cancer and had entry hematologic parameters including: an absolute neu trophil count greater than or equal to 2000 cells/mm, platelet count greater than or equal to 100,000/mm, hemo globin concentration greater than or equal to 9 g/dl. These patients may have received adjuvant chemotherapy for breast cancer, but had not received prior chemotherapy for at least 6 months prior to the time of study. Informed consent was also obtained from these patients according to guide lines previously established by the Human Investigations Committee of the Indiana University School of Medicine, which adheres to the principles of the Declaration of Hels All patients received cancertherapy with high-dose cyclophosphamide on day 0 of study, Thereafter, hematopoietic growth factors were administered by continuous intravenous infusion at the dose and schedule detailed in this table. In patient PIXY 321 -recombinantly engineered GM-CSF fusion.
Peripheral blood (PB) and bone marrow (BM) cell sepa ration techniques.
Peripheral blood (PB) was collected using the methodol ogy described by Sienna et al., Blood, Vol. 74, p. 1905 (1989 from patients in Group A (patients ML1, 2, 3, 4 and 6 on day +12, +13, or +14, patientML5 on day 0 and on day +12) (Table 4 ) and patients in Group B. The whole blood was erythrocyte depleted by gravity sedimentation with 33% Emagel (Behring, Scoppito, Italy) for 30 minutes at 37° C. and a leukocyte enriched fraction obtained (see, Sienna et al., Blood, Vol. 77, p. 400 (1991) . The PB was then sus pended in 50 ml of Iscove's modified Dulbecco's Medium (IMDM) supplemented with 15-20% of fetal calf serum (FCS). All samples were packaged on ice and processed in within 48 hours from the time of collection. The viability of these cells at the time of study ranged from 92% to 98% as assessed by typan blue exclusion. Small BM samples (1-2   50   55   60   65 CSF was escalated by 1 g/kg every SF up to 5 g/kg/day. BC -breast cancer.
IL-3 cells even though both HLA-DR and CD15 were FITC conjugated. Cells stained with both markers display two distinct green fluorescence peaks. The "dim" peak corre sponding to HLA-DR is between 1 and 1.5 logs less fluo rescent than the "bright" peak corresponding to CD15. Simultaneous staining with PE-conjugated CD34; FTTC HLA-DR cells. The CD34" HLA-DR cell population is enriched for differentiated marrow progenitor cells includ ing (CFU-GM), (BFU-E), megakaryocyte-colony-forming unit (CFU-MK) and granulocyte-erythroid-macrophage megakaryocyte-colony-forming-unit (CFU-GEMM), while the CD34 HLA-DR or CD34 HLA-DR CD15 cell populations are enriched for several classes of primitive hematopoietic progenitor cells including blast-colony forming-unit (CFU-B1), (HPP-CFC), burst-megakaryocyte forming-unit (BFU-MK) and long-term bone marrow culture-initiating cells (LTBMC-IC).
In 4 patients (2 each from Groups A and B), a multicolor staining protocol was used to also determine c-kit (KR) expression on CD34" HLA-DR cells. The SR-1 antibody to the c-kit receptor was used as described above.
Hematopoietic growth factors. -Recombinant human stem cell factor (SCF, specific activity, 5x10U/mg), IL-3 (Specific activity 10 U/mg) and GM-CSF (specific activity, 107 U/mg) were obtained from Amgen Inc., Thousand Oaks, Calif. Human urine erythro poietin (Epo, specific activity, 34.8 U/mg) was purchased from Toyobo Co., LTD., Japan Long-term suspension cultures. Stromal cell-free long-term marrow or PB cultures (ITBMC) or (LTPBC) were initiated and maintained gen erally as described above. Sorted PB CD34 HLA-DR or BM CD34 HLA-DR CD15 cells (1x10/ml) were seeded inflat-bottomed 24-well plates in 1 ml IMDM supplemented with 10% FCS, SCF 100 ng/ml and IL-3 1 ng/ml, and incubated at 37 C. in 100% humidified 5% CO in air. Every 48 hours thereafter, cultures received SCF 100 ng/ml and IL-3 1 ng/ml. At weekly intervals, the cultures were demi-depopulated by the removal of half the culture volume which was then replaced by fresh medium and cytokines. Cells in the harvested medium were counted and assayed for CFU-GM and BFU-E.
Hematopoietic progenitor cell assays. Freshly sorted PB or BM CD34 HLA-DR and CD34' HLA-DR cells (1x10/ml) and cellular aliquots obtained from LTPBC or LTBMC (1x10"/ml) were suspended in 34-mm plastic tissue culture dishes (Costar Data Packing, Cambridge, Me.) containing 1 ml of 30% FCS, 5x10M 2-mercaptoethanol, 1 U human urine Epo, 100 ng/ml SCF, 1 ng/ml IL-3, 200 pg/ml GM-CSF and 1.1% methylcellulose in IMDM. The cultures were incubated at 37° C. in 100% humidified 5% CO, in air. After 14 days, CFU-GM, BFU-E and CFU-GEMM colonies yielded by CD34" HLA-DR" cells, or after 28 days HPP-CFC colonies yielded by CD34' HLA-DR cells were enumerated in situ using an inverted microscope and standard criteria for their identification.
BFU-MK and CFU-MK were assayed in a serum depleted assay system detailed by Briddell et al. in Blood. Vol. 79, p. 3159 (1992) . The BFU-MKassay was initiated with either 5x10/ml of PB CD34t HLA-DR or BM CD34
HLA-DR CD15 cells while the CFU-MK assay was initiated with 5x10/ml of PB or BM CD34 HLA-DR" cells. Freshly sorted cells were suspended in a 1 ml serum depleted fibrin clot containing 100 ng/m. SCF and 1 ng/ml IL-3 and incubated at 37° C. in a 100% humidified atmo sphere containing 5% CO in air. After 12 days (for CFU MK) and 21 days (for BFU-MK), the cultures were fixed in situ and stained using 10E5 mouse monoclonal IgG anti bodies recognizing platelet glycoproteins Dib-IIIa complex (provided by Dr.Barry S. Coller State University of New York-Stoney Brook, N.Y.) and a fluorescein-labeled, affinity-purified goat anti-mouse IgG (H+L) (Kirkegaard and Perry Laboratories). BFU-MK or CFU-MK colonies were enumerated utilizing an epifluorescent microscope accord ing to established criteria (see, Briddellet al., Blood, Vol. 79, p. 3159 (1992) ).
Statistical analysis.
The results expressed as the mean-SEM were obtained from duplicate experiments. Statistical significance was determined using the Mann-Whitney U test.
B. Results
The hematopoietic progenitor cells (HPC) and PHSC content of various PB and BM cell subpopulations was initially assessed by monitoring cell phenotypes. The num ber of CD34" cells/ml was used as a measure of both HPC and HSC contentinaparticular cell population while CD34 HLA-DR"/ml was utilized to quantitate HPC numbers and the numbers of CD34 HLA-DR/ml and/or CD34 HLA DRSR-1"Iml served as a means of quantitating changes in PHSC numbers (Table 5) (Table 5 ). In contrast, 13.09.2x10/ ml of CD34" HLA-DRSR-1" cells were present in the PB following HD-CTX+C-HGF (Group A) ( Table 5 ). The fre quency of CD34, CD34" HLA-DR and CD34 HLA-DR cells in Group APBMCs was comparable to that present in BM aspirated from breast cancer patients (Group C) (Table   5) The number of assayable HPC present in PBMC follow ing HD-CTX+C-HGF (Group A) was also compared to PBMCs collected from a comparable patient population not receiving this therapy (Group B). HD-CTX+C-HGF admin istration resulted in a statistically significant greater number of circulating CFU-GM (p less than 0.01), BFU-E (p less than 0.01), CFU-GEMM (pless than 0.01) and CFU-MK (p less than 0.01) (Group A vs. Group B) (Table 6 ).
Furthermore, HD-CTX+C-HGF administration lead to a mobilization of BFU-MK (Table 6 ). The BFU-MK were readily detected in the PBMC of Group A patients but not Group B patients (1.3-0.9x10°/ml in Group A vs. 0.00.0/ 50 55 mlin Group B, p<0.01) ( Table 6 ). The number of CFU-GM, BFU-E, CFU-MK and BFU-MKassayed from PBMC after HD-CTX+C-HGF(Group A) was comparable to the number detected in BM obtained from Group C patients (Table 6) . By contrast, greater numbers of CFU-GEMM were present in PBMNC of Group A patients than in the BM of Group C patients (Table 6 ). In fact, there was a 13-fold greater number of CFU-GEMM numbers present in one ml of PB from Group A patients than in one ml of BM obtained from Group C patients (Table 6) . No HPP-CFC were assayable from either the PBMNC of Group A or B patients but were assayed from the marrow obtained from Group C patients (Table 6) CFU-GM, BFU-B and CFU-GEMM were assayed from 1 x 10 of PB or BM CD34' DR'cells/ml and emunerated on day 14. The individual cultures were supplemented with 100 ng/ml SCF, 1 ng/ml IL-3, 200 pg/ml GM-CSF and 1 UEml Epo. The HPP-CFC were assayed from 1 x 10 of PB or BMCD34' DR cella/mlandenumeratedonday 28. The individual cultures were supplemented with 100ng/mlSCF, 1 ng/ml IL-3, 200 pg/ml GM-CSF and 1 U/mlExpo. The CFU-MK and BFU-MK were assayed from 5 x 10 of PB or BM CD34 DR' (for CFU-MK) or CD34 DR (for BFU-MKyml and enumerated on day 12 (for CFU-MK) and day 21 (for BFU-MK). The individual cultures were supplemented wiht 100 ng/ml SCF and 1 ng/ml IL-3. The absolute number of colonies/ml of PB or BM was calculated as described in the legend of (FIG. Sa) , assayable CFU-GM for an average of 9 weeks (range 8-10 weeks) (FIG. Sb) and BFU-E for an average of 4 weeks (range 2-6 weeks) ( Table 7) .
If one compares the ability of PB CD34" HLA-DR CD15 cells in Group C (FIG.5a-b) , one observes that both Group A and Group C CD34" HLA-DR cells produced peak numbers of cells and CFU-GM on weeks 8 and 6 of culture respectively. PB CD34" HLA-DR obtained from (Table 7) . Cumulative production of BFU-E during the period of suspension culture was significantly greater when PB CD34" HLA-DR cells from patients in Group A served as the initiating cell population than when the BM CD34' HLA-DR CD15 cells from patients in Group C were used to initiate the LTBMC (10.7+5.3x10'/ml cultures vs. 1.5+0.8x10/ml cultures, p<0.01) (Table 4) Cultures were seeded at 1 x 10'lml of peripheral blood CD34 HLA-DR or bone marow CD34
HLA-DR CD15 cells and supplemented with 100 ng/ml of SCF and 1 ng/ml of IL-3 every 48 hours. Absolute numbers of BFU-E were calculated as described in the legend of 
BM cells from breast cancer patients in Indianapolis not treated with HD-CTX or growth factors. ND -not determined
The ability of HD-CTX+C-HGF to mobilize both HPC 35 and PHSC was further confirmed by examining the HPC  TABLE 8 te te e pati 4.
CO nt of PBMC collected from on patient (ML5 , Table 4 ) Effect of cyckophosphamide and growth factors administration on the both prior to (day 0) and following HD-CTX+C-HGF (day mobilization of hematopoietic progenitor cells and stem celis 12). As can be seen in Tables 8 and 9, HD-CTX+C-HGF 40 into the peripheral blood of a breast cancer patient.
therapy resulted in a 180-fold increase in the numbers of PBMC CD34 cells, a 228-fold increase in the numbers in CD34 HLA-DR cells, a 38-fold increase in the numbers of CFU-GM, a 25-fold increase in the numbers of circulating BFU-E, and a 228-fold increase in the numbers of circulat ing CFU-GEMM (Table 8 ). In this particular patient, PB CD34 HLA-DR cells were detected only after completion of the mobilization protocol. In addition, PB CFU-MK and BFU-MK were present on day 12 but not onday 0 (Table 8) . PB CD34" HLA-DR cells obtained on day 0 did not sustain long-term hematopoiesis in vitro (Table 9 ). LTPBC initiated with PB CD34 HLA-DR cells isolated on day 12 were capable of producing viable cells for 12 weeks and assayable CFU-GM for 10 weeks and BFU-E for 4 weeks ( Table 9 ).
Cohorts of patients in Group A were treated with high-dose cyclophosphamide followed by several different growth factor combinations (patients ML1, 4, 5, IL-3+ GM-CSF; patients ML2, 3, IL-3+G-CSF and patient 6 PDXY-321) (Table 4 ). There was no significant differences in the effects of these growth factor combinations on the mobilization of HPC and HSC (Tables 5-7) . Absolute mumber of colonies (X 10/ml PB) The mumber of CD34, CD34t HLA-DRtor CD34t HLA-DR cells/ml of PB was calculated as described in the legend of Table 2. CFU-GM, BFU-E and CFUGEMM were assayed from 1 x 10 of PBCD34' DR cells/ml and enumerated on day 14. The individual cultures were supplemented with 100 ng/ml SCF, 1 ng/ml IL-3, 200 pg/ml GM-CSF and 1
Ulml Epo. The CFU-MK and BFU-MK were assayed from 5 x 10 of PB CD34* HLA-DR' (for CFU-MK) or CD34* HLA-DR (for BFU-MKyml and enumerated on day 12 (for CFU-MK) and day 21 (for BFU-MK). The individual cultures were supplemented with 100 ng/ml SCF and 1 ng/ml L-3.
Each point represents mean of duplicate assay.
The absolute number of colonies/ml of PB was calculated as described in the legend of Table 2. 5,672,346 23 Absolute number of cells (x 10'lml culture) Cultures were seeded at 1 x 10/ml of PB CD34t HLA-DR cells and Eglia 100 ng/ml SCF and 1 ng/ml IL-3 every 48 hours.
Asolute cell numbers and numbers of CFUGM and BFU-E were calculated as described in the legend of (specific gravity 1.077 g/mL, Pharmacia Fine Chemicals, Piscataway, N.J.). Counterflow centrifugal elutriation of low density BM cells was than performed as described above. Briefly, cells were injected in phosphate-buffered saline (PBS), pH 7.4 containing 5% fetal bovine serum (FBS), 0.01% EDTA withvol, and 1.0 g/L D-glucose into an elutria tor system with a standard separation chamber (Beckman, Palo Alto, Calif.). Rotor speed and temperature were main tained at 1,950rpm and 10° C. Fractions elutin at a flow rate of 12 and 14 mL/min were collected, pooled, and used for cell staining and sorting.
Immunofluorescence staining and cell sorting. Monoclonal antibodies CD34 (purified HPCA-1, IgG isotype, and fluorescein isothiocyanate (FTTC)-conjugated HPCA-2), CD15 (Leu-M1, IgM isotype), and phycoerythrin (PE)-conjugated HLA-DR (IgG isotype) were obtained from Becton Dickinson Immunocytrometry Systems, San Jose, Calif. FTTC-conjugated QBEND 10 (CD34) was obtained from AMAC, Westbrook, Me. R123 and allophy cocyanin (APC)-streptavidin were obtained from Molecular Probes, Eugene, Oreg. Texas red (TR)-conjugated goat-anti mouse IgG and biotinylated goat-anti-mouse IgM were obtained from Southern Biotechnology, Birmingham, Ala. Cell staining for four-color flow cytometric cell sorting using R123, PE, TR, and APC was carried out as described by Srour et al., Cytometry, Vol. 12, p. 179 (1991) . Briefly, cells washed with PBS supplemented with 2% (wtwol) bovine serum albumin (BSA) were first incubated for 20 minutes with appropriate amounts of CD34 and CD15 simultaneously. Following that, TR-conjugated goat-anti mouse IgG and biotinylated goat-anti-mouse IgM were added to develop the CD34 and CD15 respectively. Mouse myeloma proteins were then added to blockfree active sites on the second-step reagents. Finally PE-conjugated HLA DR, R123 (used at 1 g/mL) and APC-streptavidine were kept at 4°C. in the darkthroughout staining and cell sorting. Conjugated and purified isotypematched nonspecific myeloma proteins were used to determine background fluo rescence and establish positivity. When R123 was not used in cell staining, FTTC-conjugated CD15 (BDIS, San Jose, Calif.) was substituted for purified CD15 in conjunction with PE-conjugated HLA-DR and CD34, which was devel oped with a TR-conjugated second step reagent.
Cell sorting was performed on a Coulter Epics 753 dual laser flow cytometer (Coulter Corp, Hialeah, Fla.) capable of simultaneously detecting five parameters and equipped with a CICERO high-speed cell sorting computer (Cytomation, Fort Collins, Colo.) Cytometer settings capable of adequately measuring R123 and PE fluorescences simulta neously as well as specifications of optical filters used to separate the four different wavelengths generated from the four fluorochromes were used as previously described. A gating bit map generated on a dual fluorescence (TR/PE) histogram was first constructed to select for CD34 HLA events. These selection criteria for R123 were based on the rationale described by Mulder et al., Exp. Hematol, Vol. 15, p.99 (1987) . Cells were sorted at a rate of 3,000 to 4,000 cells per second. Postsort cell viability, as determined by trypan blue exclusion, was always greater than 96%.
DNA analysis. Staining of cultured cells for cell cycle analysis was performed according to the methodologies of Srour et al., J.
Immunol. Vol. 148, p. 817 (1992) . Briefly, cells collected from LTBMC were stained with equal volumes of staining buffer (0.1 mg/mL propidium iodide--0.6% Nonidet P-40 in PBS) and 2 mg/mL RNase. The samples were then agitated and kept on ice in the dark for 30 minutes then analyzed on a FACScan flow cytometer calibrated with chicken eryth rocytes. For each sample, 5 to 10x10 cells were analyzed using the SFIT software (BDIS) to determine the percentage of cells in the Go-G (Go/G), the S, and the G-M phases of the cell cycle. Cultured cells were also stained at different time intervals with FTTC-conjugated CD34 (HPCA-2, BDIS, or QBEND10; AMAC) and PE-conjugated HLA-DR and analyzed for expression of these markers on a FACScan flow cytometer.
TBMC.
Stromal cell-free LTBMC were initiated and maintained using the methodologies described above. Sorted cells were seeded on day 0 at 10" cells/mL in flat-bottomed 24-well plates in IMDM supplemented with 10% fetal calf serum (FCS), and incubated at 100% humidified 5% CO in air. At day 0, and every 48 hours thereafter, cultures were fed with 1% BSA/PBS (control group), 10 to 25 ng c-kit ligand, 10 ng fusion protein (FP) (synthetic interleukin-3/granulocyte macrophage colony-stimulating factor IL-3/GMCSF) molecule, P1XY321) or a combination of both. Ltd., Osaka, Japan), 10 ng/mL c-kitligand, 10 ng/mlFP, and 1.1% methylcellulose in IMDM. Cultures were incubated at 37° C. in 100% humidified 5% CO in air. Erythropoietic bursts (BFU-E), granulocyte macrophage (CFU-GM), and mixed lineage (CFU-GEMM) colonies were enumerated 14 days later, whereas HPP-CFC-derived colonies were enu merated on day 28.
Cells harvested from LTBMC were assayed for CFU megakaryocyte (CFU-MK) colonies in a serum-depleted method of Bruno et al., Exp, Hematol, Vol. 16, p. 371 (1988) . Cells were suspended in a 1-mL serum-substituted fibrin clot with 100 U L-3 in 35-mm culture dishes and incubated at 37° C. in a 100% humidified atmosphere containing 5% CO in air. Two weeks to 18 days later the cultures were fixed in situ and stained using rabbit anti human platelet glycoprotein antisera, and FITC-conjugated goat F(ab')-specific anti-rabbit IgG (Tago, Inc., Burlingame, Calif.). MK colonies were enumerated on a fluorescence microscope and a positive colony was defined as a cluster of three or more fluorescent cells.
Secondary replating of primary HPP-CFC-derived colo nies. HPP-CFC colonies growing in semisolid medium were plucked on day 28 from the methylcellulose under direct microscopic visualization using sterile 100 L. glass micropipettes (Drummond Scientific Comany, Broomall, Pa.) and suspended in 200 L IMDM. The cell suspension was then made up to 1 mL, containing at a final concentra tion 1.1% methylcellulose, 30% FBS, 5x10 mol/L 2-mercaptoethanol, 1 U human purified erythropoietin, 10 ng/mL c-kit ligand, and 10 ng/mL FP, which was then transferred entirely into a single well of a 24-well tissue culture plate (Corning Glass Works, Corning, N.Y.). Plates were incubated at 37° C in 100% humidified air with 5% CO. Secondary CFU-GM-and HPP-CFC-derived colonies were enumerated 14 and 28 days later, respectively, as Before using R' cells for experiments aimed at expanding PHPC into vitro, it was important to establish the HPP-CFC content of BM populations isolated on the basis of their staining with R123. Hematopoietic progenitor cell assays of sorted R and R cells showed that between 9% and 43% of CFU-GM, BFU-E, and CFU-GEMM cloned from CD34 HLA-DRCD15 marrow cells were present in the R fraction. On the other hand, the majority of assayable HPP-CFC were found in R* cells (Table 10) . "A total of 10 sorted R' or R' cells were cultured in 35-mm tissue culture dishes containing 1 mL of 30% FCS, 5x 10 mol-L2-mercaptoethanol, 1U
human purified erythropoietin, 10 mg/mL c-kit ligand, 10 ng/mLFP, and 1.1% methylcellulose in IMDM. Each point represents the meant SD of two (donors 2 and 4), four (donor 3), or five (donor 1) replicates.
Cell and HPP-CFC expansion in LTBMC. Cellular content as well as numbers of progenitor cells in both R-and R-initiated LTBMC increased during the culture period, albeit to a different magnitude and at different rates. In response to repeated additions of c-kit ligand and FP, cellular expansion in R' cultures reached its peak at week 6 with more than a 1500-fold increase in cell number (Table 11 ). Under the same conditions, a mere sevenfold increase in cell number at week 3 was observed in R LTBMC. Only LTBMC initiated with R" cells continued to produce cells for 10 weeks, indicating that LTBMC-IC were primarily present in the R' fraction of CD34" HLA-DR CD15 BM cells. Abbreviation: ND, not determined.
"Viable cell number = cells/mL culture/(4)", where n = mumber of previous -ulations.
tSorted RandR cells were maintained in 1 mL of IMDM containing 10% FCS and were supplemented by the addition of 10 nghmLFP and 25 mg/mL. c-kit ligand every 48 hours.
To monitor the expansion of HPP-CFC during the period of LTBMC, one half of the cells in R-and R-initiated LTBMC was removed at weekly intervals and assayed for HPP-CFC as well as for CFU-GM-and CFU-MK-derived colonies. LTBMC initiated with R cells did not contain any assayable CFU-GM, HPP-CFC, or CFU-MK progenitor cells after 3 weeks of culture (Table 12) . However, CFU GM-and CFU-MK-derived colonies continued to be present after 8 weeks in cultures initiated with R cells (Table 12 ). In R initiated cultures, HPP-CFC were assayable 4 weeks after the initiation of the cultures but not by week 6. Over a period of 3 weeks, more than a twofold increase in the number of HPP-CFC originally present in the culture at day 0 was detected. Furthermore, there was an overall 5.5-fold increase in HPP-CFC numbers during the entire period of LTBMC. Similar data were observed in two other experi ments. However, the degree of HPP-CFC expansion varied 5, 672, 346 27 among cultures such that one LTBMC initiated with R cells resulted in a more than eightfold increase in the number of assayable HPP-CFC at week 3. Abbreviation: NT, not tested for lack of R cells at indicated tine point.
Harvested cells at various concentrations were assayed for CFU-GM and HPCC in 35-mm tissue culture dishes as described in Table 1 . CFUGM derived colonies and HPP-CFC were enumerated on days 14 and 28, respectively, and based on the number of total viable cells per culture from Table 2 , the total number of colonies per culture was calculated. The assay of CFU-MK-derived colonies was performed in 1 mL serum-substituted fibrin clotto which 10 cells and 100 UIL-3 were added. Colonies were enumerated after 14 to 18 days of incubation using rabbitanti-human plateket glycoprotein antisera. The number of CFU-MK colonies was corrected to reflect the total numbedculture.
Sorted R and R cells were maintained in 1 mL IMDM containing 10% PCS and were supplemented by the addition of 10 ng/mLFP and 25 mg/mL c-kit ligand every 48 hours.
Expansion of CD34" HLA-DR cells in vitro.
To examine, in an alternative fashion, the capacity of R' cells to support in vitro expansion of PHPC, the number of cells displaying the original CD34" HLA-DR phenotype was monitored during the period of LTBMC. The loss of CD34 expression or the acquisition of HLA-DR have been shown to occur in differentiating hematopoietic cells in vitro. Results generated from three consecutive weekly analyses of the LTBMC described in Tables 11 and 12 showed that compared with the isotype control, 37% of the cells after 14 days in culture in the presence of c-kit ligand and FP displayed the original CD34* HLA-DR phenotype. The percentage of CD34 HLA-DR cells in these cultures at weeks 3 and 4 decreased to 13% and 2%, respectively. This cell population was undetectable by week 5.
We then determined the absolute number of CD34 HLA DR cells present in LTBMC at different time points (Table  13) *Sorted R' cells were maintained in 1 mLIMDM containing 10% FCS and were supplemented by the addition of 10 ng/mLFP and 25 ng/mL c-kitligand every 48 hours. Experiments were performed to examine which cytokines were responsible for the expansion of PHPC in vitro.
Because sufficient numbers of R and R cells needed for such studies are difficult to isolate from BM aspirate samples, and R123 fluorescence persists in isolated cells for prolonged periods preventing further accurate flow cytomet ric analysis, CD34" HLA-DR CD15 cells were used in these studies. This cell subpopulation was cultured for 7 days in the presence of c-kit ligand and FP, alone or in combination, and cells were then analyzed for CD34 and forward angle light scatter). In addition, 68% of cells exposed to c-kit ligand expressed CD34 and 75% of these cells remained in Go/G. Relative to the cell number at day 0, only a 1.1-fold increase in cell number was detected in these LTBMC. By contrast, 88.5% of cells receiving FP lacked CD34 expression, whereas 42.5% of these cells had exited from Go/G, resulting in a 10-fold increase in cell number. Approximately a 15-fold increase cell number was observed in LTBMC receiving c-kit ligand and FP, with 45% of these cells entering into S and G-M phases of the cell cycle. This cellular expansion coupled with the fact that 20% of these cells expressed the original CD34" phenotype indicated that in these cultures, a 2.9-fold increase in the number of CD34" cells was achieved.
Replating of primary HPP-CFC colonies. PHPC expansion was investigated by replating day 28 primary HPP-CFC cloned from R' cells in the presence of c-kit ligand and FP ( see FIG. 6 ). Based on the type of secondary colonies formed after replating, three groups of primary HPP-CFC colonies could be identified. The first group (10%) were unable to sustain the growth of any type of secondary colonies. The second group of colonies (47%) contained cells capable of giving rise to only secondary CFU-GM colonies. Individual primary HPP-CFC colonies of this type each contained between 1 and 25 CFU-GM. Primary HPP-CFC-derived colonies that made up the third group (43% of all colonies analyzed) contained cells that, in addition to being capable of giving rise to secondary CFU GM colonies (14.24.9 mean-SD); range 6 to 26 CFU GM/primary HPP-CFC), also formed secondary HPP-CFC derived colonies. Arange of one to six with an average of 3.5 secondary HPP-CFC were formed on the replating of such individual primary HPP-CFC. In utero transplantation.
BM graft cells (CD34", HLA-DR cells obtained as described above) were injected into several 42-to 48-day old sheep fetuses intraperitoneally through a 22-gauge needle using general techniques as described by Flake et al., Science, Vol. 233, p. 766 (1986) . Briefly, the uterus of a pregnant ewe was accessed through a midline laparotomy incision. A traverse incision was then made through the myometrium and chordin. The BM graft was injected intra peritoneally into the fetus after manipulating it into an amniotic bubble. The myometrium was then closed in a double layer and the pregnancy allowed to proceed to term except in two fetuses that were killed in utero 30 days later. Hematopoietic progenitor cell assays. Cells assayed for the generation of hematopoietic colonies were obtained from the BM of a control sheep, the human donor of the graft, and the chimeric sheep (sheep 4038) as well as CD45 and CD45 BM cells from sheep 4038 isolated by flow cyto metric sorting. Also, a mixture of 95% control sheep and 5% normal human BM cells was prepared and assayed for hematopoietic progenitor cells. Progenitor cell assays were performed as described by Brandt et al., J. Clin, Invest, Vol. 86. p. 932 (1990) Modified Dulbecco's Medium, and either 1 U human puri fied erythropoietin (Epo; 50 U/mg protein); Toyobo Co. Ltd., Osaka, Japan) or 1 ng interleukin-3 (IL-3) plus 1 ng granulocytemacrophate colony-stimulating factor (GM CSF). IL-3 and GM-CFS were obtained from Genzyme Corp (Boston, Me...) . The cultures were incubated at 37° C. in a 100% humidified atmosphere of 5% CO in air. Eryth ropoietic colonies (CFU-E) were enumerated after 6 days, whereas erthropoietic bursts (BFU-E) were counted after 9 and 14 days using standard criteria for their identification. Propagation of T lymphocytes in vitro. Propagation of T lymphocytes from sorted chimeric CD45 and CD45 BM cells was performed as previously generally described. See, Srour et al., Clin. Exp. Immunol, Vol. 80, p. 114 (1990) . Briefly, round-bottomed 96-well plates were seeded with 10' inradiated (5,000 rad) cells of CD45" or CD45 chimeric BM cells) were added at 50 cells per well. The plates were incubated at 37° C. in a 100% humidified atmosphere of 5% CO in air for 14 days and were fed with 10 Lwell of TCGF on day 7. Wells seeded with either CD45" or CD45 BM cells that contained colonies were harvested, pooled, and the cells stained for flow cytometric immunofluores cence analysis as described above.
Variable number tandem repeat polymorphism analysis. DNA was isolated from BM cells from the chimeric sheep at 3 months after birth, BM cells of a control sheep, and the donor of the human BM graft according to published meth ods. See, Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Springs Harbor, N.Y., Cold Spring Harbor Laboratory (1989) . DNA was digested by Hat EI and electrophoresed on a 1% agarose gel. The gel was then dried and probed directly (see, Cockerill, Anal Biochem, Vol. 168, p. 451 (1988) ) with radiolabeled pYNH24 (courtesy of Dr. Y. Nakamura, University of Utah) and MS31 (Cellmark Diagnostics, Germantown, Md.) using a random primed DNA labeling kit (Bothringer Mannheim, Indianapolis, Ind.). Vol. 233, p. 766 (1986) . Table 14 Table 14 ) human adult BM cells. At 2 months after birth (5 months after engraftment), PB and BM samples from sheep 4038 were obtained for analysis. Low density BM cells from a control sheep were not reactive with any of the mouse antihuman cell surface marker MoAbs used. However, when BM cells from sheep 4038 were analyzed, it became evident that a fraction of its cells representing 6% of the low-density BM cells analyzed was reactive with the leukocyte common antigen CD45 that identifies a family of glycoproteins (180 to 220 that are expressed on the surface of a variety of human hematopoi etic cells. See, Ralph et al., EMBO, Vol., 6, p. 1251 (1987 . Hematol, Vol. 15, p. 10 (1987) and such a small percentage of cells (0.06% when considering that only 6% of the chimeric BM cells are human) would be difficult to detect.
Cells expressing human cell surface markers were also apparent among the PB cells of sheep 4038. The various cell lineages, however, were present in the PB at lower percent ages than what was observed in BM. Of particular interest is the fact that PB CD4 or CD8" T lymphocytes were present in numbers threefold to fivefold less than those found in BM, even though a total of 2.5% of PB cells expressed CD3. Chimeric PB also contained human NK cells, as evidenced by the detection of cells expressing CD16 and CD56, as well as a small percentage (0.2%) of CD19 lymphocytes. PB cells from a control sheep were completely unreactive with the MoAbs used in these assays.
Although the use of this battery of mouse MoAbs recog nizing human cell surface antigens proved to be species specific, two alternative methods to document the presence of human cells in the PB and BM of sheep 4038 were used to confirm the sustained engraftment. First, cytogenetic analysis was implemented to examine the karyotypes of cells present in the PB of sheep 4038 at 5 months after engraftment. Among 87 total cells examined from a preparation, 12 cells had a human karyotype. In another assay, the pattern obtained in a variable number tandem repeat analysis of donor-derived BM DNA was compared with that obtained from DNA isolated from BM cells from sheep 4038 six months after engraftment. The variable number tandemirepeat pattern of DNAisolated from the BM of sheep 4038 was completely homologous to that of donor derived DNA. These data demonstrated the persistence of chimerism in this sheep at 6 months posttransplantation.
Using the different electrophoretic mobilities of human and sheep hemoglobins in a variety of gel matrices, the presence of human hemoglobin in the peripheral blood of CFU-E-and BFU-E-derived colonies present in the BM of a control sheep appeared on days 6 and 9 of culture, respectively. These colonies, however, degenerated by day 14. Similarly, when cultured in the presence of human recombinant IL-3 and GM-CSF, few sheep CFU-GM derived colonies appeared by day 9. When chimeric BM cells (obtained at 5 months after engraftment) were cultured under the same conditions, about 10-fold and sixfold more BFU-E and CFU-GM-derived colonies, respectively, were present on day 14 as compared with the number of colonies present on day 14 in cultures of control sheep BM cells. The presence of BFU-E-derived colonies with human BFU-E growth kinetic characteristics suggests that human erythro poiesis was established in this animal, albeit not to a sufficient level to allow detection of human hemoglobin in the PB of this animal. On day 14, cells from CFU-GM derived colonies in cultures initiated with chimeric BM cells were plucked, washed, and prepared for karyotypic analysis. Although the karyotype of only a few cells could be posi tively identified, all of these cells were of human origin.
To further confirm that human progenitor cells were present in the chimeric BM of sheep 4038, flow cytometric cell sorting was used. From 2.5x10 chimeric BM cells Clin. Exp. Immunol, Vol. 80, p. 114 (1990) . Cells from the developing T-lymphocyte colonies were collected 14 days later and their phenotype was determined flow cytometri cally. The results of the analysis of cells collected from T-lymphocyte colonies generated from CD54 and CD45 fractions of chimeric BM showed that colonies that devel oped from CD45T cells contained cells that failed to react with any of the human T-cell-specific MoAbs as well as with CD45 and HLA-DR. On the other hand, CD45 BM cells gave rise to colonies containing cells greater than 98% of which were CD45 and CD3. In addition 89.4% of these cells were positive for the expression of CD7, while 57.0% were CD8 and 30.8% CD4". Detection of myeloid, erythroid, and megakaryocytic lin eages in chimeric sheep. The ability of chimeric BM cells to form human hemato poietic colonies was assessed 190 days following in utero transplantation. Human cells present within the chimeric BM of sheep 273 and 306 were identified and isolated by flow cytometric cell sorting based on their reactivity with CD45. Isolated CD45" (human in origin) and CD45T (sheep in origin) cells were used along with-human and control sheep BM cells in hematopoietic progenitor cell assays to determine which human cell lineages were being expressed in the transplanted sheep. The assays were evaluated on day 12 for the enumeration of colony forming unit megakaryocyte (CFU-MK), on day 14 for the enumeration of BFU-E. CFU-GM, and CFU-GEMM and on day 28 for the presence of HPP-CFC. Whereas control sheep BM cells and CD45T cells from sheep 273 and 306 failed to give rise to any CFU-MK-derived colonies, CD45 cells from both animals contained megakaryocytic progenitor cells. Similar results were obtained for both BFU-E-and CFU-GEMM derived colonies. However, CD45 cells from sheep 306 did not give rise to these types of colonies although in a previous similar experiment conducted 144 days post-transplantation, BM cells from sheep 306 generated BFU-E-and CFU GEMM-derived colonies. Also, at 190 days post transplantation, CD45 cells from sheep 273 and 306 con tained granulocytic/monocytic progenitor cells in numbers equal to or in excess of those detected in normal human low density BM cells. The fact that some CFU-GM-derived colonies were observed in marrow cells of a control sheep and in the CD45T fraction of sheep 273 and 306 BM cells is not surprising. Although sheep marrow cells do not respond maximally to stimulation with human recombinant cytokines, a partial response is usually detected. Evidence of self-renewal in transplanted sheep. With self-renewal being a seminal functional parameter of HSC, whether the human BM graft used in these experi ments contained cells capable of self-regeneration was investigated. To achieve this, chimeric BM cells collected 120 days post-transplantation were analyzed flow cytometri cally for the presence of CD34" HLA-DR cells. Since human cells in the chimeric BM constituted a small fraction of total BM cells, human CD45" cells were first isolated by flow cytometric cell sorting and then stained and analyzed for the expression of CD34 and HLA-DR. The phenotype of cells used initially as a BM graft was detected in sheep BM. In addition, cells expressing other human lineages were also detected with such analysis. It is of interest to note that the percentage of chimeric human BM cells expressing the CD34" HLA-DR phenotype was higher than what is nor mally present in human BM cells. It is possible that a selective pressure to proliferate and expand was exerted on human CD34" by the "non-permissive" sheep BM microen vironment. The fact that a higher percentage of human CD34 cells existed in the chimeric BM than in normal BM may in turn explain why a higher number of human hemato poietic colonies was detected in the former than in the latter.
Taken together, these data demonstrate that the BM grafts transplanted into fetal sheep in these studies consist of human HSC capable of both pluripotent differentiation and self-renewal. It is also apparent from these studies that the sheep-human model of xenogeneic stem cell transplantation provides a unique avenue for the in vivo examination of human hematopoiesis. Although several other animal mod els have been previously utilized for this purpose, none has had much success without the co-transplantation into the host animals of other human tissues in addition to hemato poietic cells nor was any capable of supporting pluripoten tial lymphohematopoiesis as demonstrated by applicants' work. In fact, differentiation of human cells in some of these animal models has been reported to occur in the transplanted human tissues, such as human thymus, and not in the animal host perse suggesting that these models represent no more than just a modified form of allogeneic BM transplantation rather than a xenogeneic model of human hematopoiesis. In addition, most of the animal models utilizing immunodefi Thus the applicants have demonstrated for the first time the ability of a given phenotype of human BM cells to undergo multipotential lymphohematopoiesis and self renewal in a single "assay system". In fact these data are the first ever to show that a well characterized, phenotypically homogeneous population of BM cells was capable of mul tipotential differentiation simultaneously giving rise to cells belonging to the erythrocytic, megakaryocytic, granulocytic as well as the B, T, and NK lymphoid lineages. Also important is the fact that it is an in vivo model of human hematopoiesis and that it allows for the in vivo self-renewal of HSC. Since in these studies on CD34 HLA-DR BM cells constituted the stem cell grafts it becomes clear that not only are these cells responsible for the observed engraftment but that this phenotype of BM cells is identified with the human pluripotential hematopoietic stem cell. In addition to other utilities, the successful engraftment offetal sheep with purified adulthuman HSC evidence the applicability of such cells and cells from other like sources (e.g. fetal liver, umbilical cord blood, peripheral blood) to prenatal stem cell transplantation in humans for the correction of several hematological and metabolic disorders. The data from the applicants' discoveries suggest that such purified HSC could be used across histocompatibility barriers providing ample supply of stem cells for transplantation patients.
While the invention has been illustrated and described in the foregoing description, the same is to be considered as illustrative and not restrictive in character, it being under stood that only the preferred embodiments have been shown and described and that all changes and modifications that come within the spirit of the invention are desired to be protected.
All publications cited herein are hereby incorporated by reference herein as if each were individually incorporated and fully set forth. Additional information may be found in U. S. Pat. No. 5,061,620 and in Srour et al., Blood, Vol. 79, No. 6, pp. 1404 -1412 (1992 ; Srour et al., Blood, Vol. 81, pp. 661-669 (1993); and Briddell et al., Blood, Vol. 79, pp. 3159-3167 (1992) , which are also hereby incorporated by reference herein in their entirety.
What is claimed is:
1. A method of obtaining persistent maintenance of grafted human hematopoietic cells in a mammal, comprising the step of grafting the mammal in utero with a pluripotent human stem cell (PHSC) containing population of non-fetal
